At Mount Sinai Medical Center, our oncology department is dedicated to providing the best care for our patients with #UterineCancer. Dr. Brian Slomovitz, the Director of Gynecologic Oncology, is at the forefront of detecting and treating uterine cancer through innovative treatments and clinical trials. As the Uterine Cancer Lead for GOG Partners, Dr. Slomovitz approaches all his cases with precision and kindness. Having successfully treated many uterine cancer patients, Dr. Slomovitz exemplifies the dedication of our medical center in giving our patients a second chance. Check out one of our patient stories by clicking the link to learn more: https://bit.ly/45tpQ5T #UterineCancerAwareness #WombCancer #WomensHealth #EndometrialCancer
Mount Sinai Medical Center of Florida’s Post
More Relevant Posts
-
Today, we mark Metastatic Breast Cancer Awareness Day with a firm commitment to patients and ongoing clinical research endeavors. At MEDSIR, our focus remains on advancing metastatic breast cancer research through ongoing studies such as: PARSIFAL https://lnkd.in/dNDWC7jA BIOPER https://lnkd.in/d4bHmAxj ATRACTIB https://lnkd.in/gDHtynyZ In close collaboration with leading oncology researchers, we diligently design and oversee clinical trials to contribute to our collective knowledge and understanding of this complex disease. Together, let's raise awareness and support ongoing research for the benefit of patients and their families. #MetastaticBreastCancer #ResearchMatters #CancerResearch #MEDSIR #ClinicalTrials
To view or add a comment, sign in
-
-
Our work is directly changing hospital protocols for ALK-positive lung cancer patients. An oncologist, after consulting with ALK Positive Lung Cancer UK and reviewing the "Good Practice from the Patients' Perspective"* guide is transitioning from yearly to 6-monthly brain MRIs as standard care. This significant move, sparked by a patient's informed advocacy and our support, underscores the power of collaboration in evolving patient care strategies. “My oncologist is now seeking to change procedure for all ALK patients at the hospital so 6-monthly brain MRIs become part of standard care. It just shows what you can do with an oncologist who’s open to listening and the support of ALK Positive UK." This change marks a real advancement in patient care, driven by our collective effort and expertise. * read our guide ➡️ https://lnkd.in/e_B2qdgA #PatientAdvocacy #Oncology #LungCancer #ALKPositive
To view or add a comment, sign in
-
-
Over the last decade, the Advanced Prostate Cancer (APC) landscape has evolved rapidly with a rising incidence and increasing disease complexity. With an increasing number of APC patients, it is important for advanced practice providers, or APPs, to stay up to date with the latest clinical guidelines, such as the American Urological Association Advanced Prostate Cancer Guideline, a collaboration with the Society of Urologic Oncology, Inc, so they can partner effectively with urologists and ensure that patients receive the best possible care through their APC clinic. That’s why we continue to build on our legacy in #ProstateCancer to help support those impacted by this disease. We are committed to supporting APC clinics across the care continuum and ensuring APC providers have the tools they need to keep up to date with these advancements while caring for APC patients. Watch as Michael White, PA-C, shares more: https://bit.ly/46O914y
To view or add a comment, sign in
-
Today marks an important day for Novartis Oncology Gulf. Today marks our partnership with the Emirates Oncology Society. Today marks our commitment towards excellence & innovation, into elevating breast cancer care accross the United Arab Emirates, & the Gulf countries. But most importantly, today reinforces our commitment towards breast cancer patients. #breastcancerawarenessmonth #breastcancer #breastcancerawareness #breasthealth #breastcancercare #womeninpink #novartis #NovartisGulf #EmiratesOncologySociety
To view or add a comment, sign in
-
-
A new clinical guideline in the treatment of patients with breast cancer was recently published by the National Cancer Control Programme (NCCP). The guideline was developed by a multi-disciplinary group chaired by Dr Eve O’Toole, Head of Evidence and Quality Hub in the NCCP, who explained that they “worked with radiation oncology clinicians and engaged with patient representatives to develop this evidence-based guideline. We integrated their clinical experience and patient values with the best current evidence to formulate recommendations for clinical practice. The patient focus group provided views of those who are most impacted by its recommendations, and their valuable feedback shaped the overall guideline.” https://bit.ly/44YEj8v #OurHealthService #CancerCare #NewTreatments #HealthcareInnovation #BreastCancer
To view or add a comment, sign in
-
-
Due to a limited number of treatment options and a poor prognosis, triple negative breast cancer (TNBC) can be particularly difficult to manage. To optimize treatment, clinicians need to ensure that their priorities are aligned with patients' goals and perspectives. Check out this educational program to hear an expert panel of oncology professionals engage in an in-depth discussion about patient-centered care practices for triple negative breast cancer. The panelists discuss current and emerging treatment approaches, especially second-line therapies and strategies for advanced/metastatic TNBC, and assess how these modalities can help patients reach their personal treatment goals. They also explore patient gaps, disparities, and perspectives regarding involvement in clinical trials. Discover essential updates in TNBC care today: https://bit.ly/46OcSzE
To view or add a comment, sign in
-
💪 At Servier, we are dedicated to combatting blood and pediatric cancers. We believe that every patient deserves the best possible care. 👧👦 We are currently stepping up our research in pediatric cancer. We aim to ensure that these young patients have a brighter, healthier future. 🧑⚕️To achieve these goals, we dedicate over 50% of our R&D budget to oncology, with a particular focus on immuno-oncology research, to develop targeted therapies to cure hard-to-treat cancers. To learn more about our engagements for #BloodCancersAwarenessMonth and #ChildhoodCancerAwarenessMonth, please visit 👉 https://lnkd.in/drYg6tgH #Servier #ServierBeLux #WeAreServier #MovedByYou #PediatricCancers #BloodCancer #Servier2030 #OncologyResearch #ChildhoodCancer #GoldSeptember
To view or add a comment, sign in
-
💪 At Servier, we are dedicated to combatting blood and pediatric cancers. We believe that every patient deserves the best possible care. 👧👦 We are currently stepping up our research in pediatric cancer. Our goal is to ensure that these young patients have a brighter, healthier future. 🧑⚕️To achieve these goals, we dedicate over 50% of our R&D budget to oncology, with particular focus on immuno-oncology research, in order to develop targeted therapies to cure hard-to-treat cancers. To learn more about our engagements for #BloodCancersAwarenessMonth and #ChildhoodCancerAwarenessMonth, please visit 👉 https://swll.to/RDFIi #WeAreServier #MovedByYou #PediatricCancers #BloodCancer #Servier2030 #OncologyResearch #ChildhoodCancer #GoldSeptember
To view or add a comment, sign in
-
#BreastCancer remains the most commonly diagnosed cancer for women in Europe, impacting nearly 29.4% of women. The estimated incidence rate of breast cancer in women in Europe varies greatly. This can be due to where organised breast cancer screening programmes have been carried out and the different prevalence. This week we are attending the European Society of Medical Oncology's #ESMOBreast24, where we hope to learn about practice-changing new data to define a clear roadmap to ensure better care for those living with breast cancer 🎗️ #DaiichiSankyoEurope
To view or add a comment, sign in
-
Can we detect appendix cancer early? "As per studies, the 5-year survival rate for neuroendocrine tumors of the appendix with a size less than 3 cm is 100%." Although it does not have any major causes, appendix cancer is generally seen among smokers or those with a family history of this cancer. In this video, Dr. (Maj. Gen.) B.N. Kapur, Director, Medical Oncology talks about the symptoms of appendix cancer. Do watch it now! For appointments, call us at 9810709038, 0120-4612000. #appendixcancer #cancerawareness #cancercare #cancerexcellence #bestoncologists #bestcancerdoctors #yashodacancerinstitutes #yashodahealthcare
To view or add a comment, sign in